KRYS Krystal Biotech, Inc. - Common Stock
$299,68
Prix · Mai 20, 2026
Données fondamentales au Mai 4, 2026
Fourchette 52 semaines
$123–$319
90% of range
Note des analystes
BUY
18 analysts
Objectif de cours
$323
+8% upside
P/E (TTM)
36.0
ROE
18.1%
Marge nette
52.6%
KRYS Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$299.68
Capitalisation Boursière
$7.20B
P/E (TTM)
36.0
BPA (TTM)
$6.84
Revenus (TTM)
$389M
Rendement div.
—
ROE
18.1%
Dette/Capitaux propres
—
Fourchette 52 semaines
$123 – $319
KRYS Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$389M
2021-12-31
→
2025-12-31
BPA
$6.84
2020-12-31
→
2025-12-31
Flux de trésorerie libre
$189M
2017-12-31
→
2025-12-31
Marges
52.6%
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
KRYS
Médiane des pairs
P/E (TTM)
36.0
26.3
P/S (TTM)
18.5
15.7
P/B
5.9
8.4
Price / FCF (Cours / FCF)
38.1
—
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
KRYS
Médiane des pairs
Operating Margin (Marge d'exploitation)
41.4%
—
Net Profit Margin (Marge nette)
52.6%
-15.1%
ROA
17.1%
-24.9%
ROE
18.1%
-42.1%
ROIC
14.3%
—
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
KRYS
Médiane des pairs
Current Ratio (Ratio de liquidité)
10.0
5.1
Quick Ratio (Ratio de liquidité réduite)
6.1
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
KRYS
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
33.9%
—
EPS YoY (BPA Année/Année)
128.0%
—
Net Income YoY (Bénéfice net YoY)
129.7%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
KRYS
Médiane des pairs
KRYS Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
18 analystes
- Achat fort 7 38,9%
- Achat 9 50,0%
- Conserver 2 11,1%
- Vente 0 0,0%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
9 analystes · 2026-05-21
Médiane
$310.00
Moyenne
$322.78
Maintenant
$299.68
Bas
$241.00
Haut
$399.00
Objectif médian
$310.00
+3,4%
Objectif moyen
$322.78
+7,7%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
0.43%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 31 mars 2026 | $1.83 | $1.45 | 0.38% |
| 31 décembre 2025 | $1.70 | $1.44 | 0.26% |
| 30 septembre 2025 | $2.66 | $1.11 | 1.6% |
| 30 juin 2025 | $1.29 | $1.15 | 0.14% |
| 31 mars 2025 | $1.20 | $1.39 | -0.19% |
Comparaison avec les pairs Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| IBRX | $2.00B | -5.2 | 668.3% | -310.2% | 71.0% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| NUVL | — | -17.2 | — | — | -38.9% | — |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 14
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $389M | $291M | $51M | $0 | $0 | |
| R&D Expense | $58M | $54M | $46M | $42M | $28M | |
| SG&A Expense | $147M | $114M | $98M | $78M | $40M | |
| Operating Expenses | $228M | $225M | $160M | $145M | $68M | |
| Operating Income | $161M | $66M | $-110M | $-145M | $-68M | |
| Interest Expense | · | · | $0 | $0 | $1M | |
| Pretax Income | $189M | $95M | $13M | $-140M | $-70M | |
| Income Tax | $-15M | $6M | $2M | $0 | $0 | |
| Net Income | $205M | $89M | $11M | $-140M | $-70M | |
| EPS (Basic) | $7.08 | $3.12 | $0.40 | $-5.49 | $-3.13 | |
| EPS (Diluted) | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 | |
| Shares (Basic) | 28,944,000 | 28,592,000 | 27,154,000 | 25,492,000 | 22,196,846 | |
| Shares (Diluted) | 29,951,000 | 29,740,000 | 27,752,000 | 25,492,000 | 22,196,846 | |
| EBITDA | $161M | $66M | $-110M | $-141M | $-66M |
Bilan 22
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $496M | $345M | $358M | $162M | $341M | |
| Receivables | $127M | $105M | $42M | $0 | · | |
| Inventory | $40M | $27M | $7M | $0 | · | |
| Prepaid Expense | $15M | $12M | $7M | $5M | $4M | |
| Current Assets | $1.02B | $742M | $588M | $384M | $442M | |
| PP&E (Net) | $151M | $155M | $161M | $162M | $112M | |
| PP&E (Gross) | $182M | $177M | $174M | $168M | $117M | |
| Accum. Depreciation | $31M | $22M | $13M | $7M | $4M | |
| Other Non-current Assets | $287.0K | $231.0K | $263.0K | $324.0K | $74.0K | |
| Total Assets | $1.33B | $1.06B | $818M | $558M | $626M | |
| Accounts Payable | $3M | $5M | $4M | $4M | $8M | |
| Current Liabilities | $103M | $102M | $33M | $29M | $26M | |
| Capital Leases | $8M | $6M | $7M | $7M | $7M | |
| Other Non-current Liabilities | $4M | $1M | $0 | · | · | |
| Total Liabilities | $114M | $109M | $40M | $36M | $33M | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | |
| Paid-in Capital | $1.19B | $1.13B | $1.05B | $804M | $735M | |
| Retained Earnings | $24M | $-181M | $-270M | $-281M | $-141M | |
| AOCI | $1M | $-190.0K | $638.0K | $-728.0K | $-163.0K | |
| Stockholders' Equity | $1.22B | $946M | $779M | $522M | $594M | |
| Liabilities + Equity | $1.33B | $1.06B | $818M | $558M | $626M | |
| Shares Outstanding | 29,192,000 | 28,794,000 | 28,237,000 | 25,763,743 | 25,207,985 |
Flux de trésorerie 14
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| D&A | · | · | · | $4M | $3M | |
| Stock-based Comp | $55M | $49M | $40M | $33M | $15M | |
| Deferred Tax | $-27M | $0 | $0 | $0 | $0 | |
| Other Non-cash | · | · | · | $2M | $4M | |
| Operating Cash Flow | $201M | $123M | $-89M | $-101M | $-48M | |
| CapEx | $12M | $4M | $12M | $53M | $68M | |
| Investing Cash Flow | $-58M | $-163M | $83M | $-114M | $-227M | |
| Stock Issued | $0 | $0 | $160M | $29M | $356M | |
| Net Stock Activity | $0 | $0 | $203M | $36M | $356M | |
| Financing Cash Flow | $9M | $27M | $203M | $35M | $348M | |
| Net Change in Cash | $151M | $-13M | $196M | $-179M | $73M | |
| Taxes Paid | $15M | $6M | $0 | $0 | · | |
| Free Cash Flow | $189M | $119M | $-101M | $-154M | $-116M | |
| Levered FCF | · | · | $-101M | · | · |
Rentabilité 7
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Operating Margin | 41.4% | 22.6% | -216.4% | · | · | |
| Net Margin | 52.6% | 30.7% | 21.6% | · | · | |
| Pretax Margin | 48.7% | 32.8% | 25.4% | · | · | |
| EBITDA Margin | 41.4% | 22.6% | -216.4% | · | · | |
| ROA | 17.1% | 9.5% | 1.6% | -23.6% | -14.8% | |
| ROE | 18.1% | 9.7% | 1.4% | -26.3% | -13.9% | |
| ROIC | 14.3% | 6.5% | -11.9% | · | · |
Liquidité et Solvabilité 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 10.0 | 7.3 | 17.8 | 13.3 | 17.2 | |
| Quick Ratio | 6.1 | 4.4 | 12.1 | 5.6 | 13.3 | |
| Interest Coverage | · | · | · | · | -45.8 |
Efficacité 2
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.1 | · | · | |
| Receivables Turnover | 3.4 | 2.8 | 2.4 | · | · |
Taux de croissance 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue YoY | 33.9% | 473.0% | · | · | · | |
| EPS YoY | 128.0% | 669.2% | · | · | · | |
| Net Income YoY | 129.7% | 715.6% | · | · | · |
Valorisation (TTM) 10
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue TTM | $389M | $291M | $51M | $0 | $0 | |
| Net Income TTM | $205M | $89M | $11M | $-140M | $-70M | |
| Market Cap | $7.20B | $4.51B | $3.50B | $2.04B | $1.76B | |
| P/E | 36.0 | 52.2 | 318.1 | -14.4 | -22.3 | |
| P/S | 18.5 | 15.5 | 69.1 | · | · | |
| P/B | 5.9 | 4.8 | 4.5 | 3.9 | 3.0 | |
| P / Tangible Book | 5.9 | 4.8 | 4.5 | 3.9 | 3.0 | |
| P / Cash Flow | 35.8 | 36.5 | -39.4 | -20.3 | -36.8 | |
| P / FCF | 38.1 | 37.8 | -34.8 | -13.3 | -15.2 | |
| Earnings Yield | 2.8% | 1.9% | 0.31% | -6.9% | -4.5% |
Compte de résultat 14
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $116M | $107M | $98M | $96M | $88M | $91M | $84M | $70M | $45M | $42M | $9M | $0 | $0 | $0 | |
| R&D Expense | $15M | $15M | $15M | $14M | $14M | $14M | $14M | $16M | $11M | $11M | $11M | $12M | $12M | $12M | |
| SG&A Expense | $41M | $41M | $38M | $35M | $33M | $31M | $29M | $28M | $26M | $25M | $24M | $26M | $24M | $20M | |
| Operating Expenses | $63M | $63M | $56M | $57M | $52M | $50M | $61M | $62M | $52M | $39M | $35M | $38M | $49M | $31M | |
| Operating Income | $54M | $44M | $41M | $39M | $36M | $41M | $22M | $9M | $-7M | $3M | $-26M | $-38M | $-49M | $-31M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Pretax Income | $61M | $51M | $48M | $47M | $44M | $49M | $30M | $16M | $932.0K | $11M | $81M | $-33M | · | · | |
| Income Tax | $6M | $-268.0K | $-31M | $8M | $8M | $3M | $3M | $477.0K | $0 | $2M | $0 | $0 | · | · | |
| Net Income | $56M | $51M | $79M | $38M | $36M | $45M | $27M | $16M | $932.0K | $9M | $81M | $-33M | $-45M | $-30M | |
| EPS (Basic) | $1.91 | $1.77 | $2.74 | $1.33 | $1.24 | $1.60 | $0.95 | $0.54 | $0.03 | $0.53 | $2.88 | $-1.25 | $-1.76 | $-1.17 | |
| EPS (Diluted) | $1.83 | $1.69 | $2.66 | $1.29 | $1.20 | $1.53 | $0.91 | $0.53 | $0.03 | $0.61 | $2.79 | $-1.25 | $-1.76 | $-1.17 | |
| Shares (Basic) | 29,288,000 | -57,734,000 | 28,953,000 | 28,910,000 | 28,815,000 | -57,017,000 | 28,716,000 | 28,598,000 | 28,295,000 | -53,257,000 | 28,042,000 | 26,657,000 | 25,712,000 | 25,619,125 | |
| Shares (Diluted) | 30,507,000 | -59,502,000 | 29,833,000 | 29,749,000 | 29,871,000 | -59,090,000 | 29,902,000 | 29,637,000 | 29,291,000 | -53,509,000 | 28,892,000 | 26,657,000 | 25,712,000 | 25,619,125 | |
| EBITDA | $54M | · | $41M | $39M | $36M | · | $22M | $9M | $-7M | · | $-26M | $-38M | $-49M | $-31M |
Bilan 22
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $501M | $496M | $393M | $354M | $309M | $345M | $374M | $346M | $359M | · | $373M | $276M | $141M | $186M | |
| Receivables | $127M | $127M | $130M | $111M | $103M | $105M | $97M | $103M | $46M | · | $9M | · | · | · | |
| Inventory | $43M | $40M | $38M | $31M | $30M | $27M | $19M | $12M | $11M | · | $5M | · | · | · | |
| Prepaid Expense | $16M | $15M | $17M | $17M | $17M | $12M | $9M | $8M | $6M | · | $5M | $6M | $5M | $3M | |
| Current Assets | $1.02B | $1.02B | $926M | $841M | $767M | $742M | $713M | $683M | $602M | · | $582M | $484M | $355M | $398M | |
| PP&E (Net) | $154M | $151M | $149M | $150M | $151M | $155M | $157M | $159M | $160M | · | $164M | $164M | $163M | $158M | |
| PP&E (Gross) | $187M | $182M | $178M | $177M | $175M | $177M | $176M | $176M | $175M | · | $175M | $173M | $171M | $164M | |
| Accum. Depreciation | $34M | $31M | $29M | $27M | $24M | $22M | $20M | $17M | $15M | · | $11M | $9M | $8M | $6M | |
| Other Non-current Assets | $300.0K | $287.0K | $333.0K | $197.0K | $218.0K | $231.0K | $203.0K | $126.0K | $196.0K | · | $285.0K | $285.0K | $402.0K | $205.0K | |
| Total Assets | $1.40B | $1.33B | $1.24B | $1.14B | $1.07B | $1.06B | $982M | $918M | $853M | · | $790M | $684M | $532M | $576M | |
| Accounts Payable | $4M | $3M | $2M | $7M | $3M | $5M | $6M | $5M | $5M | · | $4M | $4M | $4M | $6M | |
| Current Liabilities | $108M | $103M | $91M | $87M | $79M | $102M | $90M | $72M | $48M | · | $28M | $24M | $35M | $28M | |
| Capital Leases | $7M | $8M | $8M | $8M | $8M | $6M | $6M | $6M | $6M | · | $7M | $7M | $7M | $8M | |
| Other Non-current Liabilities | $5M | $4M | $3M | $3M | $2M | $1M | $761.0K | $588.0K | · | · | · | · | · | · | |
| Total Liabilities | $120M | $114M | $102M | $98M | $90M | $109M | $96M | $79M | $54M | · | $34M | $31M | $42M | $36M | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | $0 | |
| Paid-in Capital | $1.20B | $1.19B | $1.16B | $1.15B | $1.13B | $1.13B | $1.11B | $1.09B | $1.07B | · | $1.03B | $1.01B | $816M | $791M | |
| Retained Earnings | $80M | $24M | $-27M | $-107M | $-145M | $-181M | $-226M | $-253M | $-269M | · | $-279M | $-359M | $-326M | $-249M | |
| AOCI | $-2M | $1M | $1M | $1M | $390.0K | $-190.0K | $2M | $-634.0K | $-299.0K | · | $-382.0K | $-236.0K | $-154.0K | $-1M | |
| Stockholders' Equity | $1.28B | $1.22B | $1.14B | $1.04B | $985M | $946M | $886M | $839M | $799M | $779M | $756M | $653M | $490M | $541M | |
| Liabilities + Equity | $1.40B | $1.33B | $1.24B | $1.14B | $1.07B | $1.06B | $982M | $918M | $853M | · | $790M | $684M | $532M | $576M | |
| Shares Outstanding | 29,437,000 | 29,192,000 | 28,984,000 | 28,927,000 | 28,899,000 | 28,794,000 | 28,757,000 | 28,709,000 | 28,528,000 | · | 28,194,655 | 27,974,916 | 25,796,213 | 25,709,664 |
Flux de trésorerie 11
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | $826.0K | $1M | $705.0K | $975.0K | |
| Stock-based Comp | $14M | $14M | $13M | $14M | $13M | $13M | $13M | $13M | $9M | $10M | $8M | $11M | $10M | $9M | |
| Operating Cash Flow | $80M | $78M | $40M | $53M | $31M | $53M | $59M | $-4M | $16M | $-7M | $-21M | $-34M | $-26M | $-20M | |
| CapEx | $7M | $2M | $2M | $2M | $6M | $801.0K | $1M | $1M | $1M | $2M | $2M | $3M | $5M | $14M | |
| Investing Cash Flow | $-64M | $11M | $-4M | $-11M | $-55M | $-84M | $-34M | $-19M | $-26M | $-10M | $105M | $-16M | $4M | $-15M | |
| Stock Issued | · | · | · | · | · | $0 | $0 | · | · | $10.0K | $-28M | $158M | $2M | $2M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | $2M | · | |
| Financing Cash Flow | $-10M | $16M | $4M | $2M | $-12M | $2M | $3M | $11M | $11M | $3M | $13M | $185M | $1M | $2M | |
| Net Change in Cash | $5M | $104M | $39M | $45M | $-36M | $-29M | $28M | $-13M | $678.0K | $-15M | $97M | $135M | $-21M | $-32M | |
| Taxes Paid | · | $917.0K | $18.0K | $13M | $400.0K | $515.0K | $3M | $2M | $0 | $0 | · | · | · | · | |
| Free Cash Flow | $73M | · | · | · | $25M | · | · | · | $15M | · | · | · | $-32M | · |
Rentabilité 7
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 46.1% | · | 42.3% | 40.9% | 41.0% | · | 26.8% | 12.2% | -14.8% | · | -303.8% | · | · | · | |
| Net Margin | 48.1% | · | 81.2% | 39.9% | 40.5% | · | 32.4% | 22.1% | 2.1% | · | 943.8% | · | · | · | |
| Pretax Margin | 52.8% | · | 49.0% | 48.7% | 49.4% | · | 35.5% | 22.8% | · | · | · | · | · | · | |
| EBITDA Margin | 46.1% | · | 42.3% | 40.9% | 41.0% | · | 26.8% | 12.2% | -14.8% | · | -303.8% | · | · | · | |
| ROA | 4.5% | · | 7.1% | 3.7% | 3.7% | · | 3.1% | 2.1% | 0.12% | · | 11.8% | · | -7.9% | -5.8% | |
| ROE | 5.0% | · | 7.8% | 4.1% | 4.0% | · | 3.3% | 2.2% | 0.13% | · | 12.4% | · | -8.7% | -6.3% | |
| ROIC | 3.8% | · | 6.0% | 3.1% | 3.0% | · | 2.3% | 0.99% | · | · | · | · | · | · |
Liquidité et Solvabilité 2
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.5 | · | 10.1 | 9.7 | 9.6 | · | 8.0 | 9.5 | 12.7 | · | 21.1 | · | 10.1 | 14.2 | |
| Quick Ratio | 5.8 | · | 5.7 | 5.4 | 5.2 | · | 5.3 | 6.2 | 8.5 | · | 13.9 | · | 4.0 | 6.6 |
Efficacité 2
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.0 | · | · | · | |
| Receivables Turnover | 1.0 | · | 0.9 | 0.9 | 1.2 | · | 1.6 | 1.4 | 1.9 | · | 1.8 | · | · | · |
Valorisation (TTM) 10
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $398M | · | $366M | $338M | $288M | · | $208M | $124M | $54M | · | $9M | · | · | · | |
| Net Income TTM | $209M | · | $181M | $117M | $79M | · | $124M | $64M | $3M | · | $-28M | $-136M | $-153M | $-124M | |
| Market Cap | $7.60B | · | $5.12B | $3.98B | $5.21B | · | $5.23B | $5.27B | $5.08B | · | $3.27B | · | $2.07B | $1.79B | |
| P/E | 37.0 | · | 29.1 | 35.0 | 67.5 | · | 42.7 | 87.4 | -936.5 | · | -83.5 | -22.2 | -13.3 | -14.1 | |
| P/S | 19.1 | · | 14.0 | 11.8 | 18.1 | · | 25.2 | 42.5 | 94.3 | · | 382.3 | · | · | · | |
| P/B | 6.0 | · | 4.5 | 3.8 | 5.3 | · | 5.9 | 6.3 | 6.4 | · | 4.3 | · | 4.2 | 3.3 | |
| P / Tangible Book | 6.0 | · | 4.5 | 3.8 | 5.3 | · | 5.9 | 6.3 | 6.4 | · | 4.3 | · | 4.2 | 3.3 | |
| P / Cash Flow | 94.6 | · | · | · | 168.2 | · | · | · | 319.5 | · | · | · | -79.0 | · | |
| P / FCF | 103.8 | · | · | · | 210.4 | · | · | · | 347.0 | · | · | · | -65.5 | · | |
| Earnings Yield | 2.7% | · | 3.4% | 2.9% | 1.5% | · | 2.3% | 1.1% | -0.11% | · | -1.2% | -4.5% | -7.5% | -7.1% |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $389M | $291M | $51M | $0 | $0 |
| Marge d'exploitation % | 41.4% | 22.6% | -216.4% | — | — |
| Résultat net | $205M | $89M | $11M | $-140M | $-70M |
| BPA dilué | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio de liquidité | 10.0 | 7.3 | 17.8 | 13.3 | 17.2 |
| Ratio de liquidité réduite | 6.1 | 4.4 | 12.1 | 5.6 | 13.3 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $189M | $119M | $-101M | $-154M | $-116M |
Dernières actualités Actualités récentes mentionnant cette entreprise
- Ce qu'il faut savoir sur ce développeur de médicaments contre l'obésité qui vient de recevoir un nouvel investissement de 7 millions de dollars
- Cette Biotech avec un médicament révolutionnaire contre la sclérose en plaques attire 8 millions de dollars d'investissement malgré une chute de 30 % de ses actions
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.